FCA
TBPH icon

FinTrust Capital Advisors’s Theravance Biopharma TBPH Stock Holding History

FinTrust Capital Advisors’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-200
Closed -$3 – 1144
2020
Q3 		$3 Buy
+200
New +$3.75K ﹤0.01% 1037

Other funds holding TBPH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

FinTrust Capital Advisors's TBPH Position: Q4 2020 in Review

FinTrust Capital Advisors sold out of Theravance Biopharma (TBPH) in Q4 2020, closing a stake of 200 shares — an estimated $3 sold.

FinTrust Capital Advisors first reported a position in TBPH in Q3 2020 and held it in 1 quarter. The position peaked at $3 in Q3 2020. 107 funds tracked by Wall St. Rank hold TBPH as of Q4 2020.

  • FinTrust Capital Advisors reported no remaining Theravance Biopharma position as of Q4 2020 after selling out during the quarter.
  • FinTrust Capital Advisors sold 200 Theravance Biopharma shares in Q4 2020, an estimated $3.
  • FinTrust Capital Advisors first reported a position in Theravance Biopharma in Q3 2020 and held it in 1 quarter.
  • FinTrust Capital Advisors's Theravance Biopharma position peaked at $3 in Q3 2020.
  • 107 funds tracked by Wall St. Rank held Theravance Biopharma as of Q4 2020.

Based on FinTrust Capital Advisors's 13F filing for Q4 2020, filed 16 Feb 2021.